Back
Full-text
Journal article

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

  • Lhermitte L Université Paris Descartes-Sorbonne Paris Cité, Institut Necker-Enfants-Malades, INSERM UMR1151, Paris, France.
  • Mejstrikova E CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
  • van der Sluijs-Gelling AJ Dutch Childhood Oncology Group, The Hague, The Netherlands.
  • Grigore GE Cytognos SL, Salamanca, Spain.
  • Sedek L Department of Microbiology and Immunology, Zabrze, Medical University of Silesia (SUM), Katowice, Poland.
  • Bras AE Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Gaipa G Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza (MB),Italy.
  • Sobral da Costa E Department of Pediatrics, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Novakova M CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
  • Sonneveld E Dutch Childhood Oncology Group, The Hague, The Netherlands.
  • Buracchi C Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • de Sá Bacelar T Department of Pediatrics, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Te Marvelde JG Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Trinquand A Université Paris Descartes-Sorbonne Paris Cité, Institut Necker-Enfants-Malades, INSERM UMR1151, Paris, France.
  • Asnafi V Université Paris Descartes-Sorbonne Paris Cité, Institut Necker-Enfants-Malades, INSERM UMR1151, Paris, France.
  • Szczepanski T Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia (SUM), Katowice, Poland.
  • Matarraz S Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
  • Lopez A Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
  • Vidriales B Hematology Service, University Hospital of Salamanca, Salamanca, Spain.
  • Bulsa J Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia (SUM), Katowice, Poland.
  • Hrusak O CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
  • Kalina T CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
  • Lecrevisse Q Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
  • Martin Ayuso M Cytognos SL, Salamanca, Spain.
  • Brüggemann M Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Verde J Cytognos SL, Salamanca, Spain.
  • Fernandez P Institute for Laboratory Medicin, Kantonsspital Aarau AG, Aarau, Switzerland.
  • Burgos L Clinica Universidad de Navarra-Centro De Investigaciones Medicas Aplicadas (CIMA), University of Navarra, Pamplona, Spain.
  • Paiva B Clinica Universidad de Navarra-Centro De Investigaciones Medicas Aplicadas (CIMA), University of Navarra, Pamplona, Spain.
  • Pedreira CE COPPE-Computation Engineering & Systems Post-graduation, Federal University of Rio de Janeiro, Rio de Janeiro(UFRJ), Brazil.
  • van Dongen JJM Department of Immunohematology and Blood Transfusion (IHB), Leiden University Medical Center, Leiden, The Netherlands.
  • Orfao A Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
  • van der Velden VHJ Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Show more…
  • 2017-11-02
Published in:
  • Leukemia. - 2018
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Female
Humans
Immunophenotyping
Infant
Infant, Newborn
Leukemia, Myeloid, Acute
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Young Adult
English Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-ALL and/or acute myeloid leukemia (AML)) and final diagnosis. Now we built a reference database with 656 typical AL samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based plots and automated classification algorithms for direct comparison of single-cells from individual patients against the database, another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the final WHO-diagnosis was already provided in >93% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT results and allows accurate selection of the relevant classification panels, hence providing a solid basis for designing future WHO AL classifications.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/55477
Statistics
Document views: 37 File downloads:
  • Full-text: 0